Ambrx Biopharma Inc. Announces Filing of Annual Report on Form 20-F
May 02 2022 - 4:05PM
Business Wire
Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage
biopharmaceutical company using an expanded genetic code technology
platform to create Engineered Precision Biologics, today announced
that it filed its annual report on Form 20-F (the “Form 20-F”) for
the year ended December 31, 2021 with the U.S. Securities and
Exchange Commission (“SEC”) on April 26, 2022. The Form 20-F can be
accessed by visiting either the SEC’s website at www.sec.gov or the
Company’s website at www.ambrx.com.
The Company will provide a hard copy of the annual report
containing its audited consolidated financial statements, free of
charge, to its shareholders and holders of its American Depositary
Shares upon request. Requests should be directed in writing by
email to ir@ambrx.com.
About Ambrx Biopharma Inc. (Ambrx)
Ambrx is a clinical stage biopharmaceutical company using an
expanded genetic code technology platform to discover and develop
Engineered Precision Biologics. These include next generation
antibody drug conjugates (ADCs), bispecifics, targeted
immuno-oncology therapies, novel cytokines to modulate the immune
system, and long-acting therapeutic peptides for metabolic and
cardiovascular disease. Ambrx is advancing a robust portfolio of
clinical and preclinical programs designed to optimize efficacy,
safety and ease of use, in multiple therapeutic areas, including
its lead product candidate ARX788. In addition, Ambrx has clinical
collaborations with multiple partners, for drug candidates
generated using Ambrx technology. For more information, please
visit www.ambrx.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220502005647/en/
Ambrx Biopharma Inc. INVESTORS Laurence Watts, Managing
Director Gilmartin Group, LLC. 619-916-7620 ir@ambrx.com
MEDIA media@ambrx.com
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
From Apr 2023 to Apr 2024